A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

NCT05378763 · clinicaltrials.gov ↗
PHASE3
Phase
SUSPENDED
Status
268
Enrollment
INDUSTRY
Sponsor class

Stopped The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.

Conditions

Interventions

Sponsor

Spectrum Pharmaceuticals, Inc